Stock fact sheet · data as of

Skinvisible, Inc. (SKVI): fair value, margin of safety and Wheel Score

Healthcare · Medical - Pharmaceuticals · United States · Speculative / Distressed

Close0.2026
GLS fair value-no model value
Margin of safety-
Wheel Score21No optionscapped: no options
Health1/9Piotroski F-score
Moat0.9/10GLS 10-year score
Market cap$1M1k shares a day
Implied vol.-no listed options
P/E-EPS -0.19
Dividend yieldnone
Beta1.60moves more than the market
Next earnings-no date recorded

Is SKVI undervalued?

At 0.2026 (close of 16 Oct 2026), SKVI has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -0.19, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.

The nightly engine files SKVI under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for SKVI

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-1.92-1047%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Skinvisible, Inc. scores only 1 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 0.9/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are high - ROIC 23.4%, ROE 10.4%, ROA -834.1% - with debt at -0.56 times equity and negative free cash flow.

Skinvisible, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score1 / 9ROIC23.4%
GLS Moat0.9 / 10ROE10.4%
Debt / equity-0.56ROA-834.1%
Free-cash-flow yield-3508338.6%Payout ratio0%
Institutions5 / 10Insiders · Congress5 · 5 / 10

Wheel Score 21: No options

No options are listed on Skinvisible, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 21) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.

Volume runs at 1k shares a day on a market cap of $1M, with a beta of 1.60 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 5 of 20.

PartPointsFrom
Value13 / 250% margin of safety
Health2 / 20Piotroski 1/9
Moat1 / 15moat 0.9/10
Premium0 / 20no option data
Stability5 / 201k shares/day, $1M cap, beta 1.60

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for SKVI in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Pharmaceuticals

The 12 companies below are the closest to Skinvisible, Inc. by market cap within the Medical - Pharmaceuticals industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
AJYG
AJ1G, Inc.
0.10370.0001-149449%2No options$1M
ASBP
Aspire Biopharma Holdings, Inc.
8.64--32No options$997K
PAVS
Paranovus Entertainment Technology Ltd.
3.222,111.23+100%39No options$3M
GCAN
Trafalgar International, Inc.
1.60108.10+99%38No options$318K
POM
POMDOCTOR Ltd
0.6429--19No options$5M
BGMS
Bio Green Med Solution, Inc.
0.83264.51+82%39No options$5M
SCNX
Scienture Holdings, Inc.
3.351.00-234%12No options$6M
INBP
Integrated BioPharma, Inc.
0.18000.9275+81%37No options$6M
BFRI
Biofrontera Inc.
0.8471--28No options$13M
ADIA
Adia Med Inc.
0.1400222.25+100%34No options$13M
CNSY
Cerenome, Inc.
1.881.39-36%13No options$14M
SCYX
SCYNEXIS, Inc.
3.96--32Weak$25M

⚖ Compare SKVI with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about SKVI

Is SKVI undervalued right now?

The GLS models could not value SKVI (the company lost money over the last twelve months, EPS -0.19, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 0.2026 against.

What is the Wheel Score of SKVI and what does it mean?

SKVI has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for SKVI?

None of the nine GLS models produced a positive value for SKVI (the company lost money over the last twelve months, EPS -0.19, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.

When does Skinvisible, Inc. report earnings next?

No upcoming earnings date is recorded for SKVI in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does SKVI have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on SKVI, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.